New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
05:49 EDTCCXIChemoCentryx CCX168 shows improvement in BVAS
ChemoCentryx reported additional Phase II data related to CCX168, an orally administered inhibitor that targets the receptor for the complement protein known as C5a, or C5aR. Data from the first two steps of the CLEAR trial show that patients receiving CCX168 showed improvements in the Birmingham Vasculitis Activity Score, or BVAS, an overall disease activity index, including efficacy observed in both the renal and the non-renal components of the BVAS. BVAS response at 12 weeks was higher in patients on CCX168 than those patients receiving the standard of care. BVAS remission (a higher threshold that is thought to require 24 weeks of treatment or longer for maximum effect) at 12 weeks was comparable to standard of care. Both non-renal and renal disease components of BVAS were improved in patients on CCX168 treatment. Additionally, as previously reported, patients treated with CCX168 as compared to standard of care showed greater improvements in renal function based on renal disease activity measurements including estimated glomerular filtration rate, urinary albumin:creatinine ratio, and urinary monocyte chemoattractant protein-1:creatinine ratio.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2015
07:56 EDTCCXIChemoCentryx pancreatic cancer data could drive upside, says JPMorgan
JPMorgan analyst Anupam Rama says ChemoCentryx (CCXI) should report before year-end initial data from the Phase 1b trial of CCX872 in pancreatic cancer. Prior data with competitor CCR2 inhibitor PF-04136309 from Pfizer (PFE) support proof-of-concept in the indication, Rama tells investors in a research note. Further, physician feedback indicates Chemocentyx's proposed benchmark for the program is appropriate, the analyst adds. Rama views ChemoCentryx as undervalued and under-followed and sees CCX872 as "relatively underappreciated." The analyst thinks the Phase 1b data could be an "upside lever" and reiterates an Overweight rating on ChemoCentryx with a $14 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use